FDA Approves Genzyme’s AUBAGIO® (teriflunomide), a Once-Daily, Oral Treatment for Relapsing Multiple Sclerosis

Keep up to date by reading the latest press releases for Genzyme.

Explore Genzyme’s history, year-by-year, including key milestones, photographs, and video clips.

View our specialized portfolio of therapies, which provide personalized treatment for patients with rare diseases.

Learn about job opportunities around the world for those who are motivated by the prospect of changing patients’ lives for the better.